Nanotechnology Now

• About Us
  
  • Advertising
  • Our Mission
  • Our Team
  • Comments
  • Friends
  • Contact
• Nanotechnology
• News
  
  • Current News
  • Press Releases
  • Submit Press
  • Press kit
  • Interviews
• Columns
• Products
  
  • Our Products
  • Books
  • Featured Books
• Directories
  
  • Companies/Academic
  • Events
  • Glossary
  • Best Of
• Career Center
• Nano-Social Network
• Nano Consulting
• My Account

Home > News > Senesco Technologies Reports On Results Of Preclinical Multiple Myeloma Studies

February 7th, 2008

Senesco Technologies Reports On Results Of Preclinical Multiple Myeloma Studies

Abstract:
Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced the results of preclinical animal studies focused on multiple myeloma that were conducted concurrently at Mayo Clinic and the University of Waterloo. The goal of these studies, which utilized two different dosing regimens, was to further test the ability of Senesco's Factor 5A technology to induce apoptosis in tumors. Additionally, the studies evaluated the efficacy of nanoparticles as a vehicle for encapsulation and delivery of Factor 5A to tumors.

SCID (severe combined immunodeficiency) mice were injected subcutaneously with human multiple myeloma cancer cells to form myeloma tumors in their flanks. Treated mice were injected intratumorally with Factor 5A therapy encapsulated in nanoparticles, while control mice received a nanoparticle without the Factor 5A therapy. One of the dosing regimens showed evidence of significant tumor regression relative to the untreated control mice, while the other showed a diminished rate of tumor growth along with some regression.

Source:
medicalnewstoday.com

Bookmark:

Related News Press

News and information

An Innovative material for the Green Earth: Simple and inexpensive process to make a material for CO2 adsorption June 17th, 2013

Polymer-coated catalyst protects "artificial leaf" June 17th, 2013

Efficient and inexpensive: Researchers develop catalyst material for fuel cells: Platinum-nickel nano-octahedra save 90 percent platinum June 17th, 2013

AXEON Acquires Assets of Leading Reverse Osmosis Systems Manufacturer June 17th, 2013

Nanomedicine

Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013

Iranian Scientists Produce Dynamometer for Nanoparticles, Biocells June 15th, 2013

Monell-led research identifies scent of melanoma: New research may lead to early non-invasive detection and diagnosis June 14th, 2013

Discovery of new material state counterintuitive to laws of physics June 14th, 2013

Discoveries

An Innovative material for the Green Earth: Simple and inexpensive process to make a material for CO2 adsorption June 17th, 2013

Polymer-coated catalyst protects "artificial leaf" June 17th, 2013

Efficient and inexpensive: Researchers develop catalyst material for fuel cells: Platinum-nickel nano-octahedra save 90 percent platinum June 17th, 2013

Iranian Scientists Produce Dynamometer for Nanoparticles, Biocells June 15th, 2013

Announcements

An Innovative material for the Green Earth: Simple and inexpensive process to make a material for CO2 adsorption June 17th, 2013

Polymer-coated catalyst protects "artificial leaf" June 17th, 2013

Efficient and inexpensive: Researchers develop catalyst material for fuel cells: Platinum-nickel nano-octahedra save 90 percent platinum June 17th, 2013

AXEON Acquires Assets of Leading Reverse Osmosis Systems Manufacturer June 17th, 2013